In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Shares of Schrödinger soared by 15% mid-day Tuesday as the company, known for leveraging quantum mechanics in medicine and material design, embraces artificial intelligence (AI) to enhance its drug ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...
Purdue partners with Eli Lilly and Merck to launch the Young Institute Pharmaceutical Manufacturing Consortium, focusing on sterile injectables.
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...